Equity · Healthcare
Oscar Health, Inc. (OSCR) perpetual futures
OSCR perpetual futures on 3 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade OSCRUSDT.
Oscar Health, Inc. is a US health insurer offering individual, family, small business, and Medicare Advantage plans, plus its +Oscar technology platform and reinsurance solutions.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
3/3 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
3 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
Tokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| OSCRxxStocks | $25.02 | -1.82% | – | $68k | Ethereum · Arbitrum · BNB Smart Chain (BEP20) · Solana |
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kThin liquidity · 1 of 3 venues absorb $10k · Typical cost: +130.6 bps
Cheapest execution: LBank · +130.6 bps
Too thin: OKX, BingX
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
OSCRTightest spread
OSCRHighest volume
OSCRFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsAnalysts
Price targets in USD| Consensus rating | Hold |
|---|---|
| Average 12-month price target | $37.43 |
| 12-month target range (low – high) | $20 – $49 |
| Ratings in the provider's consensus | 13 |
Price targets as of 2026-11-22
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 3 | 0 | 7 | 0 | 1 |
| Oct 2026 | 3 | 0 | 7 | 0 | 1 |
| Sep 2026 | 3 | 0 | 7 | 0 | 1 |
| Aug 2026 | 3 | 0 | 7 | 0 | 1 |
| Jul 2026 | 3 | 0 | 7 | 0 | 1 |
| Jun 2026 | 3 | 0 | 8 | 1 | 1 |
| May 2026 | 2 | 0 | 7 | 1 | 1 |
| Apr 2026 | 2 | 0 | 6 | 2 | 1 |
| Mar 2026 | 2 | 0 | 5 | 2 | 1 |
| Feb 2026 | 2 | 0 | 6 | 2 | 1 |
| Jan 2026 | 1 | 0 | 6 | 3 | 2 |
| Dec 2025 | 1 | 0 | 4 | 3 | 2 |
Ownership
Institutional · 2026-Q3Reference market activity
OSCR-PERPPrice performance
11Insider activity
FY2026 Q3Insider transactions
25Director Rajat Taneja received a 3,565-share grant of Oscar Health Class A Common Stock on 2026-11-13 (Form 4 filed 2026-11-17), leaving him with 3,565 shares owned.
Director Eric Jon Larsen received 3,565 shares of Oscar Health Class A Common Stock via an A-Award (a grant, not an open-market purchase) on 2026-11-13, leaving 3,565 shares owned directly.
Oscar Health director Tomer Cohen received an award of 3,565 Class A common shares on 2026-11-13 at $0.00, an A-Award grant rather than a purchase, bringing his holdings to 3,565 shares.
Oscar Health director Taneja Rajat filed a Form 3 on 2026-11-17; the single reported line shows 0 shares of common stock at $0.00, with 0 shares owned after.
Form 3 filing for Oscar Health director Tomer Cohen shows an initial holdings report: one transaction dated 2026-11-13 with 0 shares of common stock at $0.00 and 0 shares owned. No open-market purchase, sale or award is reported.
Oscar Health director Eric Jon Larsen filed a Form 3 on 2026-11-17 reporting no shares in an initial statement of beneficial ownership.
Oscar Health director David Plouffe received a grant of 641 deferred stock units (A-Award) on 2026-10-08, bringing his reported holdings to 8,176 units.
Oscar Health director Sid Sankaran received 1,472 deferred stock units in an award, leaving him with 3,533 units owned after the transaction dated Oct 8, 2026.
Oscar Health director William Gassen received an award of 698 deferred stock units (A-Award, not a purchase) on 2026-10-08, bringing his holdings to 7,769 shares.
Director Vanessa Ames Wittman sold 25,000 Class A common shares of Oscar Health at $32.24 on Sept 18, 2026, leaving 112,121 shares owned.
Oscar Health director Joshua Kushner reported J-Other transactions: 6,343,617 Class B shares converted into 6,343,617 Class A shares, plus 164,218 Class A shares disposed at $0.00.
Oscar Health director and 10% owner Thrive Partners II GP reported J-Other transactions: 6.34M Class B shares disposed and 6.27M Class B plus 6.18M Class A shares acquired, all at $0.00.
Filings
59 · Latest SEC filingsOscar Health director Tomer Cohen received an award of 3,565 Class A common shares on 2026-11-13 at $0.00, an A-Award grant rather than a purchase, bringing his holdings to 3,565 shares.
Director Eric Jon Larsen received 3,565 shares of Oscar Health Class A Common Stock via an A-Award (a grant, not an open-market purchase) on 2026-11-13, leaving 3,565 shares owned directly.
Oscar Health director Taneja Rajat filed a Form 3 on 2026-11-17; the single reported line shows 0 shares of common stock at $0.00, with 0 shares owned after.
Form 3 filing for Oscar Health director Tomer Cohen shows an initial holdings report: one transaction dated 2026-11-13 with 0 shares of common stock at $0.00 and 0 shares owned. No open-market purchase, sale or award is reported.
Oscar Health director Eric Jon Larsen filed a Form 3 on 2026-11-17 reporting no shares in an initial statement of beneficial ownership.
Director Rajat Taneja received a 3,565-share grant of Oscar Health Class A Common Stock on 2026-11-13 (Form 4 filed 2026-11-17), leaving him with 3,565 shares owned.
Oscar Health director Sid Sankaran received 1,472 deferred stock units in an award, leaving him with 3,533 units owned after the transaction dated Oct 8, 2026.
Oscar Health director William Gassen received an award of 698 deferred stock units (A-Award, not a purchase) on 2026-10-08, bringing his holdings to 7,769 shares.
Oscar Health director David Plouffe received a grant of 641 deferred stock units (A-Award) on 2026-10-08, bringing his reported holdings to 8,176 units.
Director Vanessa Ames Wittman sold 25,000 Class A common shares of Oscar Health at $32.24 on Sept 18, 2026, leaving 112,121 shares owned.
Oscar Health director and 10% owner Thrive Partners II GP reported J-Other transactions: 6.34M Class B shares disposed and 6.27M Class B plus 6.18M Class A shares acquired, all at $0.00.
Oscar Health director Joshua Kushner reported J-Other transactions: 6,343,617 Class B shares converted into 6,343,617 Class A shares, plus 164,218 Class A shares disposed at $0.00.
On September 3, 2026, CFO Richard Scott Blackley sold 28,869 Class A common shares at $31.45 each, leaving him with 1,046,108 shares.
On September 3, 2026, Janet Liang sold 10,360 Class A common shares at $31.45 per share, retaining 248,697 shares.
On September 3, 2026, Chief Accounting Officer Victoria Baltrus sold 958 Class A common shares of Oscar Health at $31.45 per share, retaining 213,631 shares.
Director Mario Schlosser sold 31,422 Class A common shares of Oscar Health at $31.45 each on September 3, 2026.
On September 3, 2026, Chief Legal Officer Adam McAnaney sold 9,092 Class A common shares at $31.45 each, holding 209,004 afterward.
Director Mario Schlosser exercised 750,000 options at $9.75 into Class B shares, converted 750,000 shares to Class A, and sold 750,000 Class A shares at $30.34-$30.79.
On August 18, 2026, CFO Richard Scott Blackley sold 18,750 Class A shares of Oscar Health at $31.74 each, leaving 56,250 shares owned.
Oscar Health director William Gassen was granted 684 deferred stock units on 2026-07-09 as compensation, not a purchase, bringing his total holdings to 7,071 shares.
Director Sid Sankaran was awarded 858 Deferred Stock Units as compensation on 2026-07-09, bringing his total holdings to 2,061 units. This was a grant, not an open-market purchase.
Director David Plouffe was awarded 681 Deferred Stock Units on 2026-07-09 as compensation, bringing his total holdings to 7,535 units. This was a grant, not an open-market purchase.
Director Mario Schlosser converted 47,500 Class B shares into 47,500 Class A shares, then sold all 47,500 Class A shares in three trades at $29.50-$31.65.
Oscar Health CEO Mark T. Bertolini sold 1,238,996 Class A common shares in 4 open-market sales on June 29-30, 2026, at prices of $28.35-$30.08. He held 7,751,570 shares after the sales.
Oscar Health CEO and director Mark T. Bertolini reported selling 1,206,310 Class A common shares across four open-market transactions on June 25-26, 2026, at prices from $28.60 to $29.79. He held 8,990,566 shares after the sales.
Oscar Health director Mario Schlosser exercised options for 660,000 shares at $9.75, converted 977,500 Class B shares into Class A stock, and sold 993,705 Class A shares at $28.95-$30.09.
Sid Sankaran, a director at Oscar Health, was awarded 8,475 Class A shares on 2026-06-04 as compensation (not a purchase), bringing his total ownership to 22,609 shares.
Oscar Health director David Plouffe received a grant of 8,475 Class A shares on 2026-06-04, bringing his total ownership to 137,121 shares.
Director Vanessa Ames Wittman was awarded 8,475 shares of Class A common stock as compensation on 2026-06-04, bringing her ownership to 137,121 shares. This was a grant, not an open-market purchase.
Director Laura W. Lang received an award of 8,475 Class A shares on 2026-06-04, a compensation grant (not a purchase), bringing her total holdings to 82,840 shares.
Director William Gassen was awarded 8,475 shares of Class A Common Stock on 2026-06-04 as compensation, bringing his total ownership to 82,840 shares.
Chief Legal Officer Adam McAnaney sold 9,859 Class A shares of Oscar Health in 2 open-market transactions on June 2, 2026, at prices between $21.74 and $22.45.
On June 2, 2026, officer Janet Liang sold a total of 12,475 Class A common shares of Oscar Health in two open-market transactions, priced between $21.74 and $22.45. Her remaining ownership dropped to 259,057 shares.
On June 2, 2026, CFO Richard Scott Blackley sold a total of 31,683 Class A common shares in two open-market transactions at prices between $21.74 and $22.45, reducing his holdings to 1,074,977 shares.
On June 2, 2026, Oscar Health's Chief Accounting Officer sold 1,523 Class A shares in two transactions at prices between $21.74 and $22.45.
Director Schlosser Mario sold 34,120 Class A common shares of Oscar Health in two open-market transactions on June 2, 2026, at prices between $21.74 and $22.45.
CFO Richard Scott Blackley sold 110,000 Class A common shares of Oscar Health at $25.03 each on May 18, 2026, reducing his holdings to 1,106,660 shares.
Oscar Health CFO Richard Scott Blackley sold 100,000 Class A common shares on May 14, 2026, in two open-market transactions priced between $23.10 and $23.79, reducing his holdings to 1,216,660 shares.
Director Jeffery H. Boyd received a grant of 3,610 deferred stock units (Award) at no cost, holding 69,858 shares after the transaction.
Director David Plouffe received a grant of 1,461 deferred stock units, now holding 6,854 total.
Director William Gassen was awarded 1,418 deferred stock units at no cost on April 9, 2026. He now holds 6,387 shares.
Director Sid Sankaran received a deferred stock unit award of 1,203 shares of Oscar Health (OSCR), reported on Form 4 filed 2026-04-13.
CEO Bertolini converted 5,733,334 RSUs into Class A shares, bought 1,000,000 shares at $11.92, and had 1,000,001 shares withheld for taxes.
Transcripts
Earnings callsFY2026 Q12026-05-06
Earnings calls
AI summary
positiveOscar Health delivered strong Q1 2026 results with $4.6 billion in revenue (53% YoY growth), 70.5% MLR (490 bps improvement), and record net income of $679 million. The company ended Q1 with 3.2 million members, up 56% YoY, driven by above-market growth during open enrollment and solid retention. Oscar reaffirmed its full-year 2026 guidance while expressing confidence in meeting or exceeding targets.
Key takeaways
- Record Q1 net income of $679 million ($2.07 per diluted share) with 15.2% operating margin, a 540 bps YoY improvement
- Membership reached 3.2 million at end of Q1 (56% YoY growth); started Q2 with 3 million paid members
- MLR improved 490 bps to 70.5% driven by disciplined pricing, claims seasonality, and $68 million favorable prior period development
- SG&A ratio hit historic low of 15.2% (60 bps improvement YoY) due to fixed cost leverage and AI-driven efficiency gains
- Launched Lucie Health Marketplace (carrier-agnostic shopping platform) and ICHRA X (data exchange connecting carriers, brokers, and platforms)
Financial highlights
- Revenue: $4.6 billion, +53% YoY; full-year guidance $18.7B-$19.0B unchanged
- Net income: $679 million vs. $275 million prior year; earnings from operations: $704 million (+$407M YoY)
- Adjusted EBITDA: $727 million (+$398M YoY); cash and investments: $8.1 billion including $279M at parent
- Insurance subsidiaries capital: $1.7 billion including $809 million excess capital driven by strong operating performance
Guidance
- Full-year 2026 revenue guidance: $18.7 billion to $19.0 billion (reaffirmed)
- Full-year 2026 MLR guidance: 82.4% to 83.4%, with Q1 lowest and Q4 highest (reaffirmed)
- Full-year 2026 SG&A expense ratio guidance: 15.8% to 16.3% (reaffirmed)
- Full-year 2026 earnings from operations guidance: $250 million to $450 million (reaffirmed); adjusted EBITDA expected ~$115M higher than earnings from operations
Q&A themes
- Risk adjustment tracking at 24% of direct premiums in Q1 vs. full-year expectation of 20%, driven by seasonally low claims and higher bronze mix; expected to normalize as new members engage benefits and hit deductibles
- Wakely market morbidity report showing market contraction tracking in line to favorable with 20-30% estimate; Oscar's claims experience and risk adjustment reserves built on market morbidity assumptions consistent with pricing
- Q1 utilization largely in line with expectations; no unusual patterns observed in churned members; flu and weather impacts minimal
- Lucie platform represents modest 2026 revenue contribution but positioned as high-margin, unregulated business with higher margins than ACA insured members; detailed financials expected at September Investor Day
Risks
- Risk adjustment higher than guidance (24% vs. 20% full-year expectation) due to seasonally low Q1 claims, though management expects normalization throughout year
- Market morbidity assumptions depend on further Wakely reports and actual claims development; any material deviation from pricing assumptions could impact full-year results
- Lucie platform financial contribution is modest in 2026 and represents early-stage business with execution risk in scaling new business model
FY2025 Q42026-02-10
Earnings calls
AI summary
positiveOscar Health achieved 28% revenue growth to $11.7 billion in 2025 but posted a $396 million operating loss due to higher-than-expected market morbidity and risk adjustment headwinds from Medicaid expansion. The company returns to profitability in 2026 with $18.7-19 billion in revenue guidance and 58% year-over-year paid membership growth to approximately 3 million members, reflecting disciplined pricing and product innovation including new lifestyle offerings.
Key takeaways
- Record open enrollment with 3.4 million members enrolled as of February 1, 2026, with 58% year-over-year growth expected in paid membership by Q2 2026
- Market share increased from 17% to 30% in 2025 footprint; membership mix shifted significantly from silver (71% to 36%) toward bronze (25% to 39%) and gold (3-4% to 25%)
- 2026 guidance of $250-450 million operating earnings represents $750 million improvement versus 2025; MLR expected to improve 450 basis points to 82.4-83.4% range despite elevated market morbidity
- SG&A expense ratio expected to improve 140 basis points year-over-year to 15.8-16.3% driven by fixed cost leverage and AI-enabled operational efficiencies
- Launched innovative products including Hello Menopause (first ACA menopause plan), Cuando la Salud (Spanish-first diabetes plan), and Hive Health (ECR plan) with above-average retention
Financial highlights
- Total 2025 revenue: $11.7 billion, up 28% year-over-year
- 2025 operating loss: $396 million; adjusted EBITDA loss: $280 million, primarily driven by $275 million Q4 risk adjustment true-up
- Full year 2025 MLR: 87.4%, up 570 basis points year-over-year; risk adjustment as percentage of direct premiums: 18.5% (up 390 basis points)
- 2026 revenue guidance: $18.7-19 billion at midpoint, representing 61% year-over-year growth; 2026 operating earnings guidance: $250-450 million at midpoint (1.9% operating margin)
Guidance
- 2026 medical loss ratio guidance: 82.4-83.4%, representing 450 basis points improvement year-over-year; risk adjustment expected at approximately 20% of direct premiums
- 2026 SG&A expense ratio: 15.8-16.3%, improving 140 basis points year-over-year; company expects Q1 MLR lowest and Q4 highest due to deductible seasonality
- Membership expected to reach approximately 3 million paid members by end of Q1 2026, declining from 3.4 million due to grace period expirations; expecting 1-2% monthly churn thereafter
- 2026 adjusted EBITDA expected to be approximately $115 million higher than earnings from operations guidance
Q&A themes
- Market morbidity and risk adjustment volatility: Company using third-party clinical data on new members and engaged with Wakeley on industry reporting to improve visibility; acknowledged risk adjustment is most difficult forecasting challenge
- Membership composition and utilization: Q4 2025 utilization modestly above expectations primarily due to members seeking care before losing subsidies; new members tracked better than pricing expectations while renewals in line with forecast
- Premium affordability and churn expectations: Passively enrolled members transitioning from $0 premium plans face highest non-payment risk; company expects meaningful disenrollment as grace periods expire due to higher deductibles on lower-income populations
- Product innovation and brand loyalty: Lifestyle products demonstrate 50% higher recommendation rates and above-average retention; direct enrollment strong on specialized products, indicating strong brand attachment
Risks
- Market morbidity risk: 2025 saw unexpected higher market morbidity from Medicaid redeterminations and program integrity initiatives resulting in $275 million Q4 risk adjustment true-up; 2026 guidance assumes incremental morbidity increases beyond 2025 levels
- Membership retention uncertainty: 400,000 members (from 3.4 million) expected to roll off by Q1 due to higher premium shock, particularly passively enrolled members transitioning from subsidized to non-subsidized plans; potential for greater churn if members unable to afford higher deductibles
- Risk adjustment estimation challenges: Company acknowledged difficulty forecasting risk adjustment due to lack of visibility into broader market performance; market composition shifted with barbell effect creating high-morbidity and lower-morbidity plan segments, increasing estimation volatility
FY2025 Q32025-11-06
Earnings calls
AI summary
mixedOscar Health reported third quarter total revenue of approximately $3 billion, up 23% year-over-year, with membership of 2.1 million, up 28%. The third quarter medical loss ratio rose about 380 basis points to 88.5%, reflecting higher market morbidity, partially offset by $84 million of favorable prior period development; the SG&A expense ratio improved about 150 basis points to 17.5%. The company reported a $129 million loss from operations, a $137 million net loss and an adjusted EBITDA loss of $101 million. Oscar reaffirmed full year 2025 guidance, though it now expects total revenue toward the low end of its $12 billion to $12.2 billion range. Management said it expects to expand margins and return to profitability in 2026, supported by a weighted average rate increase of approximately 28% and about $60 million in administrative cost reductions.
Key takeaways
- Third quarter revenue grew 23% year-over-year to approximately $3 billion on 2.1 million members, up 28%.
- The third quarter MLR rose approximately 380 basis points to 88.5% due to higher market morbidity, partly offset by favorable prior period development.
- SG&A expense ratio improved approximately 150 basis points year-over-year to 17.5%.
- Oscar resubmitted 2026 rate filings covering close to 99% of current membership, with a weighted average rate increase of approximately 28%.
- Management reiterated confidence in margin expansion and a return to profitability in 2026.
Financial highlights
- Total revenue was approximately $3 billion, a 23% increase year-over-year.
- Third quarter MLR was 88.5%, up approximately 380 basis points year-over-year, including a $130 million increase to the 2025 risk adjustment payable partially offset by $84 million of favorable prior period development.
- Loss from operations was $129 million, net loss was $137 million and adjusted EBITDA loss was $101 million in the third quarter.
- Cash and investments were approximately $4.8 billion at quarter end, including $541 million at the parent, with $1.2 billion of capital and surplus at insurance subsidiaries including $564 million of excess capital.
Guidance
- Full year 2025 total revenue is expected toward the low end of the $12 billion to $12.2 billion range.
- Full year 2025 MLR is expected in the range of 86.0% to 87.0%.
- Full year 2025 SG&A expense ratio is expected in the range of 17.1% to 17.6%, with a loss from operations of $200 million to $300 million and adjusted EBITDA loss approximately $120 million less than the loss from operations.
- 2026 planning includes a weighted average rate increase of approximately 28% and roughly $60 million of eliminated administrative costs; formal 2026 guidance was not provided.
Q&A themes
- Wakely risk adjustment data showing market morbidity increases of about 1.5 to 2 points across several markets, and expectations for year-end morbidity.
- Utilization trends by category, including elevated but moderating inpatient and favorable pharmacy, plus favorable prior period development drivers.
- Early 2026 open enrollment feedback, broker preparation and the assumption of a 20% to 30% market contraction from expiring enhanced premium tax credits.
- Competitive positioning for 2026, including the share of markets where Oscar is the lowest or second-lowest silver plan rising from 15% to 30%.
Risks
- Higher market morbidity drove a roughly 380 basis point increase in the third quarter MLR and could persist through year-end.
- The expiration of enhanced premium tax credits is expected to contract the market by 20% to 30%, with pricing and membership implications.
- Program integrity efforts and market morbidity shifts create uncertainty for 2026 risk adjustment and medical costs.
FY2025 Q22025-08-06
Earnings calls
AI summary
mixedOscar Health reported Q2 2025 revenue of $2.9 billion (up 29% YoY) with membership exceeding 2 million, but posted a $230 million operating loss primarily due to a $316 million incremental risk adjustment payable tied to higher ACA marketplace morbidity. The company reaffirmed 2025 guidance including $12-12.2 billion revenue and $200-300 million operating loss, while announcing cost reduction initiatives targeting $60 million in administrative savings for 2026 to support return to profitability.
Key takeaways
- Q2 MLR increased 12 points YoY to 91.1%, driven by market-wide morbidity increase and $316 million incremental risk adjustment payable for 2025
- SG&A ratio improved 90 bps YoY to 18.7% despite operating losses; company expects 17.1-17.6% SG&A ratio for full year 2025
- Membership grew 28% YoY to over 2 million driven by solid retention, above-market open enrollment growth, and SEP additions
- Company announced acquisitions of ICHRA-related assets (INSXCloud platform, IHC Specialty Benefits brokerage, healthinsurance.org) and partnership with Hy-Vee for branded ICHRA product launch
- Management expects market stabilization in 2026 with double-digit rate increases across the industry and projects return to profitability in 2026
Financial highlights
- Q2 2025 total revenue: $2.9 billion, up 29% YoY
- Q2 2025 MLR: 91.1%, up 12 points YoY; adjusted MLR would have been 85.1% excluding $316 million risk adjustment payable increase
- Q2 2025 operating loss: $230 million; adjusted EBITDA loss: $199 million
- H1 2025 earnings from operations: $66 million; adjusted EBITDA: $129 million
Guidance
- 2025 full-year revenue: $12.0-12.2 billion (increased from prior guidance by $850 million at midpoint)
- 2025 full-year MLR: 86-87% (up from prior expectations due to higher market morbidity)
- 2025 full-year SG&A ratio: 17.1-17.6% (improved 50 bps at midpoint vs. initial guidance)
- 2025 operating loss: $200-300 million; adjusted EBITDA loss approximately $120 million less than operating loss
Q&A themes
- Risk adjustment exposure: 2.5% of membership (approximately 50,000 members) are dual eligible for Medicaid/ACA; company expects modest benefit if members shift to Medicaid due to higher utilization profiles
- FTR recheck impact minimal: approximately 60% of members with failed-to-file status completed reconciliation; 27,000 initial population size
- Repricing confidence: management has had productive conversations with state regulators who are supportive of rate filings; expects double-digit rate increases market-wide in 2026
- Long-term targets: maintaining 5% margin target for 2027 and $2.25 EPS target, though acknowledging need to reassess after pricing season and based on 2026 membership development
Risks
- Market morbidity uncertainty: while management expects stabilization in 2026, continued program integrity efforts and low-utilizer attrition could further deteriorate risk pool; utilization patterns moderating but inpatient costs remain elevated
- Repricing execution risk: despite positive regulator feedback, final rate approval outcomes and member retention following double-digit increases remain uncertain
- Capital adequacy contingency: while excess capital position is strong at $579 million, continuation of 2025 loss trajectory could pressure capital levels; management may need to access additional leverage or capital markets funding
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Company data
Company intelligence
Updated: Nov 22, 2026, 09:25 AM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Chief executive
- Mark Thomas Bertolini
- Employees
- 2,305
- IPO date
- Mar 3, 2021
- Country
- US
- Exchange
- New York Stock Exchange
Rating factors
- Return on equityi
- 5/5
- Return on assetsi
- 4/5
- Debt to equityi
- 3/5
- Price to earningsi
- 2/5
- Price to booki
- 2/5
Company press releases
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VTI | 0.01% | 7.6M |
| IWM | 0.26% | 6.4M |
| AVUV | 0.62% | 5.9M |
| VB | 0.09% | 5.5M |
| NJM | 0.12% | 4.8M |
| VBK | 0.21% | 3.2M |
| VXF | 0.08% | 2.6M |
| FSSNX | 0.21% | 2.3M |
| IWO | 0.52% | 2.3M |
| NLO | 0.23% | 1.7M |
| FESM | 0.76% | 1.5M |
| FCAGX | 0.51% | 1.5M |
Analyst track record
How the analysts covering OSCR have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 43 | 105 |
| Analysts | 15 | 17 |
| Buy / hold / sell | 12 / 24 / 7 | 34 / 41 / 30 |
| Upgrades / downgrades / initiations | 7 / 0 / 2 | 7 / 8 / 8 |
| Price targets hit / missed | 22 / 19 (54%) | 73 / 28 (72%) |
| Avg. return after a rating (TipRanks) | +18.6% | +51.1% |
| Best / worst call | +137.9% / -46.6% | +227.1% / -46.6% |
After buy calls on this stock: median 21-day move +0.5% vs S&P 500 -0.4% (n = 36)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Stephen BaxterWells Fargo38% hit rate on this stock · 13 targets measuredHoldtarget $27.00Sep 15, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 6, 2026 | Jessica TassanPiper SandlerNov 6, 2026 | BuyReiterated | $45.00↗ | article ↗ |
| Nov 6, 2026 | Jonathan YongUBSNov 6, 2026 | HoldMaintained | $38.00↗ | article ↗ |
| Nov 6, 2026 | Andrew Mok CFABarclaysNov 6, 2026 | BuyMaintained | $49.00↗ | article ↗ |
| Oct 12, 2026 | Jonathan YongUBSOct 12, 2026 | HoldReiterated | $36.00↗ | article ↗ |
| Sep 23, 2026 | Jessica TassanPiper SandlerSep 23, 2026 | BuyMaintained | $48.00↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 43 ratings
Frequently asked questions
Where can I trade OSCR perpetual futures?
Oscar Health, Inc. (OSCR) perpetual futures trade on 3 crypto venues, including BingX, LBank, OKX. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade OSCR around the clock?
Yes. Unlike the underlying stock, OSCR perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on OSCR perpetuals?
Right now the OSCR perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to +5.5% across 3 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the OSCR perp price compare to the Oscar Health, Inc. stock?
The venue-median OSCR perp mark is $25.5 versus a reference stock price of $25.5, a basis of -0.1%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a OSCR perpetual future?
A OSCR perpetual is a derivative that tracks the price of Oscar Health, Inc. with no expiry date. It lets you take long or short exposure to Oscar Health, Inc. on crypto venues, around the clock.
What is OSCRUSDT perpetual?
OSCRUSDT is the symbol most crypto exchanges use for the Oscar Health, Inc. perpetual settled in USDT (Tether). It tracks the OSCR share price through an index, trades 24/7 with leverage and never expires.
BingX
LBank
OKX